The majority of patients diagnosed with acute myeloid leukemia (AML) or myelodysplastic syndromes (MDS) are 60 years of age or older. The expected survival and impact of the disease depend on its subtype. The goals of treatment are symptomatic palliation and prolongation of life. Cure is rarely achieved. The options for care range from intensive chemotherapy to transfusions to end-of-life care. Intensive therapy may prolong life modestly. However, the coexistence of co-morbid conditions and a lack of efficacy limit the number of candidates for intensive therapy. Therefore, most older individuals with MDS or AML receive supportive care with transfusions.
|Original language||English (US)|
|Number of pages||7|
|Journal||Annals of Long-Term Care|
|State||Published - Oct 1 2002|
ASJC Scopus subject areas
- Geriatrics and Gerontology